

# Andrea Ghelli Luserna Di RorÃ

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7058208/publications.pdf>

Version: 2024-02-01

69  
papers

791  
citations

516215

16  
h-index

552369

26  
g-index

69  
all docs

69  
docs citations

69  
times ranked

1510  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	2.4	6
2	Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. <i>Journal of Hematology and Oncology</i> , 2022, 15, 10.	6.9	33
3	CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 159.	3.5	25
4	Rearrangements of ATP5L&KMT2A in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e139-e144.	1.2	3
5	Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents. <i>Molecules</i> , 2021, 26, 683.	1.7	3
6	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
7	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	1.4	6
8	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2639.	1.7	17
9	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021, 35, 2813-2826.	3.3	15
10	Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. <i>Blood Cancer Journal</i> , 2021, 11, 7.	2.8	3
11	An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. <i>Anti-Cancer Drugs</i> , 2020, 31, 67-72.	0.7	1
12	A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. <i>Journal of Hematology and Oncology</i> , 2020, 13, 126.	6.9	135
13	Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9724.	1.8	4
14	Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 395.	1.0	4
15	CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. <i>Minerva Medica</i> , 2020, 111, 455-466.	0.3	10
16	Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future. <i>Minerva Medica</i> , 2020, 111, 395-410.	0.3	10
17	Abstract 260: Bromodomain and extra-terminal motif proteins regulate linear and circular PVT1 in acute myeloid leukemia cells under normoxia and hypoxia. , 2020, , .		0
18	Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. <i>Minerva Medica</i> , 2020, 111, 467-477.	0.3	8

#	ARTICLE	IF	CITATIONS
19	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
20	Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2019, 11, 1654.	1.7	18
21	The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?. <i>Journal of Hematology and Oncology</i> , 2019, 12, 123.	6.9	27
22	Identification of Two <i>DNMT3A</i> Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	3
23	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1951.	1.7	17
24	Abstract 2140: <i>3c-up</i> a new adult Philadelphia negative acute lymphoblastic leukemia subgroup: Novel molecular markers. , 2019, , .		0
25	Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a. , 2019, , .		0
26	The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 2019, 134, 5047-5047.	0.6	0
27	Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. , 2019, , .		0
28	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
29	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. <i>Journal of Translational Medicine</i> , 2018, 16, 172.	1.8	24
30	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	6.9	35
31	Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors. , 2018, , .		0
32	Abstract 2951: Gene expression profiling identifies new adult "triple-negative" acute lymphoblastic leukemia (ALL) subgroups. , 2018, , .		0
33	Abstract 656: Distinct pattern of alterations in TP53 mutated/deleted and wild-type high risk acute myeloid leukemia (AML) patients: Identification of new "targetable" genes/pathways. , 2018, , .		0
34	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. <i>Blood</i> , 2018, 132, 5284-5284.	0.6	0
35	Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Blood</i> , 2018, 132, 1418-1418.	0.6	1
36	Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies. <i>Blood</i> , 2018, 132, 1507-1507.	0.6	6

#	ARTICLE	IF	CITATIONS
37	The cell cycle checkpoint inhibitors in the treatment of leukemias. Journal of Hematology and Oncology, 2017, 10, 77.	6.9	54
38	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. Leukemia, 2017, , .	3.3	3
39	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 7038-7038.	0.8	2
40	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. Journal of Clinical Oncology, 2017, 35, e23207-e23207.	0.8	0
41	Microarray analysis to identify novel copy number alterations in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 11622-11622.	0.8	0
42	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 11611-11611.	0.8	0
43	Abstract 294: Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia. , 2017, , .		0
44	Abstract 4671: Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients. , 2017, , .		0
45	Abstract 1766: Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients. , 2017, , .		0
46	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 53377-53391.	0.8	34
47	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. Oncotarget, 2016, 7, 12951-12961.	0.8	28
48	Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis.. Journal of Clinical Oncology, 2016, 34, 7044-7044.	0.8	0
49	Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT).. Journal of Clinical Oncology, 2016, 34, e18520-e18520.	0.8	0
50	Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and Tj ETQq0 0 0 rgBT /Overlock 10 Tf leukemia (AML).. Journal of Clinical Oncology, 2016, 34, e18521-e18521.	0.8	0
51	Abstract 368: Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy. , 2016, , .		0
52	Abstract 2723: The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia. , 2016, , .		1
53	Abstract 4507: New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients. , 2016, , .		0
54	Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations. Blood, 2016, 128, 1678-1678.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1679-1679.	0.6	1
56	Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs. <i>Blood</i> , 2016, 128, 2808-2808.	0.6	7
57	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	6.9	28
58	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 889-898.	1.9	30
59	Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. <i>Cancer Biology and Therapy</i> , 2015, 16, 1397-1406.	1.5	22
60	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.	2.0	4
61	The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway. <i>Blood</i> , 2015, 126, 1276-1276.	0.6	3
62	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.	0.8	58
63	Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis. <i>Blood</i> , 2015, 126, 2623-2623.	0.6	0
64	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2478-2478.	0.6	0
65	Abstract 3886: Clec12a: A new AML stem cell-associated antigen. , 2014, , .		0
66	Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience. , 2014, , .		0
67	Abstract LB-105: In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. , 2014, , .		0
68	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013, 122, 2622-2622.	0.6	11
69	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience. <i>Blood</i> , 2013, 122, 3911-3911.	0.6	0